Related references
Note: Only part of the references are listed.CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects
Li Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin
I. Gouin-Thibault et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition
Fen Jiang et al.
PHARMACOGENOMICS (2017)
Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
Muh Akbar Bahar et al.
PHARMACOGENOMICS (2017)
Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes
T. Thanga Mariappan et al.
CURRENT DRUG METABOLISM (2017)
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
Chiyo K. Imamura et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment
Sung Kweon Cho et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2016)
PBPK modeling and simulation in drug research and development
Xiaomei Zhuang et al.
ACTA PHARMACEUTICA SINICA B (2016)
Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation
Yi-xi Wang et al.
ACTA PHARMACOLOGICA SINICA (2015)
Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies
Jacoline C. Bouvy et al.
DRUG SAFETY (2015)
Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease
Masaru Togashi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Bruce K. Birmingham et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations
Jasmine A. Luzum et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2015)
Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid
Hee Youn Choi et al.
PHARMACOGENETICS AND GENOMICS (2015)
ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study
Nikica Mirosevic Skvrce et al.
PHARMACOGENOMICS (2015)
Human OCT2 variant c.808G > T confers protection effect against cisplatin-induced ototoxicity
Claudia Lanvers-Kaminsky et al.
PHARMACOGENOMICS (2015)
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study
Tanja Dujic et al.
DIABETES (2015)
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach
Nikolaos Tsamandouras et al.
PHARMACEUTICAL RESEARCH (2015)
Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction
J. P. Depta et al.
PHARMACOGENOMICS JOURNAL (2015)
Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach
N. Tsamandouras et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2
Marco Ferrari et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study
Catherine E. de Keyser et al.
PHARMACOGENETICS AND GENOMICS (2014)
How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping
Paul Verbeurgt et al.
PHARMACOGENOMICS (2014)
Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach
Michel Tod et al.
AAPS JOURNAL (2013)
Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters
Barbara Gruen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects
M. Ulvestad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink
D. F. Carr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Association of ABCB1 Polymorphisms with the Antiemetic Efficacy of Granisetron plus Dexamethasone in Breast Cancer Patients
Daiki Tsuji et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
The P-Glycoprotein Transport System and Cardiovascular Drugs
Jeffrey D. Wessler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes
John F. Carlquist et al.
THROMBOSIS AND HAEMOSTASIS (2013)
A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine
Mirte M. Malingre et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions
Lara Magro et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Influence of SLCO1B1 Polymorphisms on the Drug-Drug Interaction Between Darunavir/Ritonavir and Pravastatin
Christina L. Aquilante et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting
Ankie M. Harmsze et al.
PHARMACOGENETICS AND GENOMICS (2012)
CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects
Mark Y. Chan et al.
PHARMACOGENOMICS (2012)
A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele
Marine L. Andersson et al.
PHARMACOGENOMICS (2012)
Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction
Srecko Marusic et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2012)
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
Paul A. Gurbel et al.
AMERICAN HEART JOURNAL (2011)
Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study
L. A. Donnelly et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis
Guillaume Cayla et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention
A. M. Harmsze et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Cerivastatin, genetic variants, and the risk of rhabdomyolysis
Kristin D. Marciante et al.
PHARMACOGENETICS AND GENOMICS (2011)
Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions
G. Ahlin et al.
PHARMACOGENOMICS JOURNAL (2011)
Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events
Klaus A. Tiroch et al.
AMERICAN HEART JOURNAL (2010)
Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes
Takahisa Furuta et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study
K. Zhou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
Hui-Yan Shi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
D. Sibbing et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin et al.
LANCET (2010)
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism
Yi-Jing He et al.
CLINICA CHIMICA ACTA (2009)
Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
S. V. Vormfelde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
K. K. Filipski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects
Deepak Voora et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Mrp1 Localization and Function in Cardiac Mitochondria after Doxorubicin
Paiboon Jungsuwadee et al.
MOLECULAR PHARMACOLOGY (2009)
Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
Georgia Ragia et al.
PHARMACOGENOMICS (2009)
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism
A. Kalliokoski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The Pharmacogenomics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial
Patrick Gladding et al.
Heart Lung and Circulation (2008)
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
Suttasinee Suwannakul et al.
JOURNAL OF HUMAN GENETICS (2008)
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3
Kazuhiro Kobayashi et al.
PHARMACOGENETICS AND GENOMICS (2008)
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
Zhi-Jun Wang et al.
PHARMACOGENETICS AND GENOMICS (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
Richard H. Ho et al.
PHARMACOGENETICS AND GENOMICS (2007)
Which drugs cause preventable admissions to hospital? A systematic review
R. L. Howard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients
Claude Uehlinger et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
Mikko Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Impact of the SLCOIBI polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
Michael Igel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
T Uno et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
L Wojnowski et al.
CIRCULATION (2005)
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes
M Saito et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
An association study of 43 SNPs in 16 candidate genes with atorvastatin response
JF Thompson et al.
PHARMACOGENOMICS JOURNAL (2005)
Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication
H Malhi et al.
POSTGRADUATE MEDICAL JOURNAL (2004)
Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects
T Damy et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2004)
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes
N Yasui-Furukori et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
J Mwinyi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics
Y Nishizato et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19
JY Cho et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity
BA Hamelin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
